-
1
-
-
84870859098
-
An update on progress and the changing epidemiology of causes of childhood blindness worldwide
-
Kong L, Fry M, Al-Samarraie M, Gilbert C, Steinkuller PG. An update on progress and the changing epidemiology of causes of childhood blindness worldwide. J AAPOS. 2012;16:501-507.
-
(2012)
J AAPOS
, vol.16
, pp. 501-507
-
-
Kong, L.1
Fry, M.2
Al-Samarraie, M.3
Gilbert, C.4
Steinkuller, P.G.5
-
2
-
-
0028826101
-
Hypoxic regulation of vascular endothelial growth factor in retinal cells
-
Aiello LP, Northrup JM, Keyt BA, Takagi H, Iwamoto MA. Hypoxic regulation of vascular endothelial growth factor in retinal cells. Arch Ophthalmol. 1995;113:1538–1544.
-
(1995)
Arch Ophthalmol
, vol.113
, pp. 1538-1544
-
-
Aiello, L.P.1
Northrup, J.M.2
Keyt, B.A.3
Takagi, H.4
Iwamoto, M.A.5
-
3
-
-
17244381522
-
Final results of the Early Treatment for Retinopathy of Prematurity (ETROP) randomized trial
-
discussion
-
Good WV. Final results of the Early Treatment for Retinopathy of Prematurity (ETROP) randomized trial. Trans Am Ophthalmol Soc. 2004;102:233–248; discussion 248–250.
-
(2004)
Trans am Ophthalmol Soc
, vol.102
, pp. 233-248
-
-
Good, W.V.1
-
4
-
-
34848909008
-
Combination of laser photocoagulation and intravitreal bevacizumab (Avastin) for aggressive zone I retinopathy of prematurity
-
Chung EJ, Kim JH, Ahn HS, Koh HJ. Combination of laser photocoagulation and intravitreal bevacizumab (Avastin) for aggressive zone I retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol. 2007;245:1727–1730.
-
(2007)
Graefes Arch Clin Exp Ophthalmol
, vol.245
, pp. 1727-1730
-
-
Chung, E.J.1
Kim, J.H.2
Ahn, H.S.3
Koh, H.J.4
-
5
-
-
49449116019
-
Intravitreous bevacizumab as anti-vascular endothelial growth factor therapy for retinopathy of prematurity: A morphologic study
-
Kong L, Mintz-Hittner HA, Penland RL, Kretzer FL, Chevez- Barrios P. Intravitreous bevacizumab as anti-vascular endothelial growth factor therapy for retinopathy of prematurity: a morphologic study. Arch Ophthalmol. 2008;126:1161–1163.
-
(2008)
Arch Ophthalmol
, vol.126
, pp. 1161-1163
-
-
Kong, L.1
Mintz-Hittner, H.A.2
Penland, R.L.3
Kretzer, F.L.4
Chevez-Barrios, P.5
-
6
-
-
55449105439
-
Efficacy of intravitreal injection of bevacizumab for severe retinopathy of prematurity: A pilot study
-
Kusaka S, Shima C, Wada K, et al. Efficacy of intravitreal injection of bevacizumab for severe retinopathy of prematurity: a pilot study. Br J Ophthalmol. 2008;92:1450–1455.
-
(2008)
Br J Ophthalmol
, vol.92
, pp. 1450-1455
-
-
Kusaka, S.1
Shima, C.2
Wada, K.3
-
7
-
-
79959306727
-
Bevacizumab for retinopathy of prematurity
-
author reply
-
Lim LS, Mitchell P, Wong TY, Gole GA, Camuglia JE, Ells AL. Bevacizumab for retinopathy of prematurity. N Engl J Med. 2011;364:2360; author reply 2361–2362.
-
(2011)
N Engl J Med
, vol.364
-
-
Lim, L.S.1
Mitchell, P.2
Wong, T.Y.3
Gole, G.A.4
Camuglia, J.E.5
Ells, A.L.6
-
8
-
-
79951821800
-
Efficacy of intravitreal bevacizumab for stage 3þ retinopathy of prematurity
-
Mintz-Hittner HA, Kennedy KA, Chuang AZ. Efficacy of intravitreal bevacizumab for stage 3þ retinopathy of prematurity. N Engl J Med. 2011;364:603–615.
-
(2011)
N Engl J Med
, vol.364
, pp. 603-615
-
-
Mintz-Hittner, H.A.1
Kennedy, K.A.2
Chuang, A.Z.3
-
9
-
-
84856316155
-
Combine intravitreal bevacizumab injection with laser treatment for aggressive posterior retinopathy of prematurity (APROP)
-
Wutthiworawong B, Thitiratsanont U, Saovaprut C, et al. Combine intravitreal bevacizumab injection with laser treatment for aggressive posterior retinopathy of prematurity (APROP). J Med Assoc Thai. 2011;94(suppl 3):S15–S21.
-
(2011)
J Med Assoc Thai
, vol.94
-
-
Wutthiworawong, B.1
Thitiratsanont, U.2
Saovaprut, C.3
-
10
-
-
84872500730
-
Serum concentrations of bevacizumab (Avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity
-
Sato T, Wada K, Arahori H, et al. Serum concentrations of bevacizumab (Avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity. Am J Ophthalmol. 2011;17:17.
-
(2011)
Am J Ophthalmol
, vol.17
-
-
Sato, T.1
Wada, K.2
Arahori, H.3
-
11
-
-
0037064010
-
Insulin-like growth factor 1 induces hypoxia-inducible factor 1- mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells
-
Fukuda R, Hirota K, Fan F, Jung YD, Ellis LM, Semenza GL. Insulin-like growth factor 1 induces hypoxia-inducible factor 1- mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells. J Biol Chem. 2002; 277:38205–38211.
-
(2002)
J Biol Chem
, vol.277
, pp. 38205-38211
-
-
Fukuda, R.1
Hirota, K.2
Fan, F.3
Jung, Y.D.4
Ellis, L.M.5
Semenza, G.L.6
-
12
-
-
78650203216
-
Postnatal weight gain modifies severity and functional outcome of oxygen-induced proliferative retinopathy
-
Stahl A, Chen J, Sapieha P, et al. Postnatal weight gain modifies severity and functional outcome of oxygen-induced proliferative retinopathy. Am J Pathol. 2010;177:2715–2723.
-
(2010)
Am J Pathol
, vol.177
, pp. 2715-2723
-
-
Stahl, A.1
Chen, J.2
Sapieha, P.3
-
13
-
-
84911988207
-
Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD
-
Avery RL, Castellarin AA, Steinle NC, et al. Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD. Br J Ophthalmol. 2014;98:1636–1641.
-
(2014)
Br J Ophthalmol
, vol.98
, pp. 1636-1641
-
-
Avery, R.L.1
Castellarin, A.A.2
Steinle, N.C.3
-
14
-
-
84922524632
-
-
AVASTIN (bevacizumab) solution for intravenous infusion prescribing information, Accessed March 2014
-
AVASTIN (bevacizumab) solution for intravenous infusion prescribing information. Available at: http://www.gene.com/download/pdf/avastin_prescribing.pdf. Accessed March 2014.
-
-
-
-
15
-
-
33749426139
-
The price of sight–ranibizumab, bevacizumab, and the treatment of macular degeneration
-
Steinbrook R. The price of sight–ranibizumab, bevacizumab, and the treatment of macular degeneration. N Engl J Med. 2006;355:1409–1412.
-
(2006)
N Engl J Med
, vol.355
, pp. 1409-1412
-
-
Steinbrook, R.1
-
16
-
-
54249138516
-
Monoclonal antibody pharmacokinetics and pharmacodynamics
-
Wang W, Wang EQ, Balthasar JP. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther. 2008;84:548–558.
-
(2008)
Clin Pharmacol Ther
, vol.84
, pp. 548-558
-
-
Wang, W.1
Wang, E.Q.2
Balthasar, J.P.3
-
17
-
-
24144455629
-
Pharmacokinetics and concentrationeffect relationships of therapeutic monoclonal antibodies and fusion proteins
-
Ternant D, Paintaud G. Pharmacokinetics and concentrationeffect relationships of therapeutic monoclonal antibodies and fusion proteins. Expert Opin Biol Ther. 2005;5(suppl 1):S37-S47.
-
(2005)
Expert Opin Biol Ther
, vol.5
-
-
Ternant, D.1
Paintaud, G.2
-
18
-
-
79955022978
-
Ophthalmic drug delivery systems for the treatment of retinal diseases: Basic research to clinical applications
-
Edelhauser HF, Rowe-Rendleman CL, Robinson MR, et al. Ophthalmic drug delivery systems for the treatment of retinal diseases: basic research to clinical applications. Invest Ophthalmol Vis Sci. 2010;51:5403–5420.
-
(2010)
Invest Ophthalmol Vis Sci
, vol.51
, pp. 5403-5420
-
-
Edelhauser, H.F.1
Rowe-Rendleman, C.L.2
Robinson, M.R.3
-
19
-
-
0025106266
-
Permeability of ocular vessels and transport across the blood-retinal-barrier
-
Tornquist P, Alm A, Bill A. Permeability of ocular vessels and transport across the blood-retinal-barrier. Eye (Lond). 1990; 4(pt 2):303–309.
-
(1990)
Eye (Lond)
, vol.4
, pp. 303-309
-
-
Tornquist, P.1
Alm, A.2
Bill, A.3
-
20
-
-
0032864292
-
Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125I-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration
-
Mordenti J, Cuthbertson RA, Ferrara N, et al. Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125I-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration. Toxicol Pathol. 1999;27:536–544.
-
(1999)
Toxicol Pathol
, vol.27
, pp. 536-544
-
-
Mordenti, J.1
Cuthbertson, R.A.2
Ferrara, N.3
-
22
-
-
44649092202
-
Mapping of the neonatal Fc receptor in the rodent eye
-
Kim H, Fariss RN, Zhang C, Robinson SB, Thill M, Csaky KG. Mapping of the neonatal Fc receptor in the rodent eye. Invest Ophthalmol Vis Sci. 2008;49:2025–2029.
-
(2008)
Invest Ophthalmol Vis Sci
, vol.49
, pp. 2025-2029
-
-
Kim, H.1
Fariss, R.N.2
Zhang, C.3
Robinson, S.B.4
Thill, M.5
Csaky, K.G.6
-
23
-
-
77649253359
-
FcRn receptor-mediated pharmacokinetics of therapeutic IgG in the eye
-
Kim H, Robinson SB, Csaky KG. FcRn receptor-mediated pharmacokinetics of therapeutic IgG in the eye. Mol Vis. 2009; 15:2803–2812.
-
(2009)
Mol Vis
, vol.15
, pp. 2803-2812
-
-
Kim, H.1
Robinson, S.B.2
Csaky, K.G.3
-
24
-
-
41849086985
-
Immunohistochemical localisation of intravitreally injected bevacizumab in the anterior chamber angle, iris and ciliary body of the primate eye
-
Peters S, Heiduschka P, Julien S, Bartz-Schmidt KU, Schraermeyer U. Immunohistochemical localisation of intravitreally injected bevacizumab in the anterior chamber angle, iris and ciliary body of the primate eye. Br J Ophthalmol. 2008;92: 541–544.
-
(2008)
Br J Ophthalmol
, vol.92
, pp. 541-544
-
-
Peters, S.1
Heiduschka, P.2
Julien, S.3
Bartz-Schmidt, K.U.4
Schraermeyer, U.5
-
25
-
-
80051490622
-
VEGF signalling controls GnRH neuron survival via NRP1 independently of KDR and blood vessels
-
Cariboni A, Davidson K, Dozio E, et al. VEGF signalling controls GnRH neuron survival via NRP1 independently of KDR and blood vessels. Development. 2011;138:3723–3733.
-
(2011)
Development
, vol.138
, pp. 3723-3733
-
-
Cariboni, A.1
Davidson, K.2
Dozio, E.3
-
26
-
-
79958044393
-
VEGF signaling through neuropilin 1 guides commissural axon crossing at the optic chiasm
-
Erskine L, Reijntjes S, Pratt T, et al. VEGF signaling through neuropilin 1 guides commissural axon crossing at the optic chiasm. Neuron. 2011;70:951–965.
-
(2011)
Neuron
, vol.70
, pp. 951-965
-
-
Erskine, L.1
Reijntjes, S.2
Pratt, T.3
-
27
-
-
84863317107
-
Changes of serum VEGF concentration after intravitreal injection of Avastin in treatment of diabetic retinopathy
-
Davidovic SP, Nikolic SV, Curic NJ, et al. Changes of serum VEGF concentration after intravitreal injection of Avastin in treatment of diabetic retinopathy. Eur J Ophthalmol. 2012;22: 792–798.
-
(2012)
Eur J Ophthalmol
, vol.22
, pp. 792-798
-
-
Davidovic, S.P.1
Nikolic, S.V.2
Curic, N.J.3
-
28
-
-
84875213214
-
Plasma levels of vascular endothelial growth factor before and after intravitreal injection of bevacizumab, ranibizumab and pegaptanib in patients with age-related macular degeneration, and in patients with diabetic macular oedema
-
Zehetner C, Kirchmair R, Huber S, Kralinger MT, Kieselbach GF. Plasma levels of vascular endothelial growth factor before and after intravitreal injection of bevacizumab, ranibizumab and pegaptanib in patients with age-related macular degeneration, and in patients with diabetic macular oedema. Br J Ophthalmol. 2013;97:454–459.
-
(2013)
Br J Ophthalmol
, vol.97
, pp. 454-459
-
-
Zehetner, C.1
Kirchmair, R.2
Huber, S.3
Kralinger, M.T.4
Kieselbach, G.F.5
-
29
-
-
84856539058
-
Vascular endothelial growth factor plasma levels before and after treatment of neovascular age-related macular degeneration with bevacizumab or ranibizumab
-
Carneiro AM, Costa R, Falcao MS, et al. Vascular endothelial growth factor plasma levels before and after treatment of neovascular age-related macular degeneration with bevacizumab or ranibizumab. Acta Ophthalmol. 2012;90:e25–e30.
-
(2012)
Acta Ophthalmol
, vol.90
, pp. e25-e30
-
-
Carneiro, A.M.1
Costa, R.2
Falcao, M.S.3
-
30
-
-
14344279279
-
Low IGF-I suppresses VEGF-survival signaling in retinal endothelial cells: Direct correlation with clinical retinopathy of prematurity
-
Hellstrom A, Perruzzi C, Ju M, et al. Low IGF-I suppresses VEGF-survival signaling in retinal endothelial cells: direct correlation with clinical retinopathy of prematurity. Proc Natl Acad Sci U S A. 2001;98:5804–5808.
-
(2001)
Proc Natl Acad Sci U S A
, vol.98
, pp. 5804-5808
-
-
Hellstrom, A.1
Perruzzi, C.2
Ju, M.3
-
31
-
-
37749019322
-
IGF-I, VEGF and bFGF as predictive factors for the onset of retinopathy of prematurity (ROP)
-
Villegas-Becerril E, Gonzalez-Fernandez R, Perula-Torres L, Gallardo-Galera JM. IGF-I, VEGF and bFGF as predictive factors for the onset of retinopathy of prematurity (ROP). Arch Soc Esp Oftalmol. 2006;81:641–646.
-
(2006)
Arch Soc Esp Oftalmol
, vol.81
, pp. 641-646
-
-
Villegas-Becerril, E.1
Gonzalez-Fernandez, R.2
Perula-Torres, L.3
Gallardo-Galera, J.M.4
-
32
-
-
0032758384
-
Regulation of vascular endothelial growth factor-dependent retinal neovascularization by insulin-like growth factor-1 receptor
-
Smith LE, Shen W, Perruzzi C, et al. Regulation of vascular endothelial growth factor-dependent retinal neovascularization by insulin-like growth factor-1 receptor. Nat Med. 1999; 12:1390–1395.
-
(1999)
Nat Med
, vol.12
, pp. 1390-1395
-
-
Smith, L.E.1
Shen, W.2
Perruzzi, C.3
-
33
-
-
0025352643
-
Growth patterns of low birth weight preterm infants: A longitudinal analysis of a large, varied sample
-
Casey PH, Kraemer HC, Bernbaum J, et al. Growth patterns of low birth weight preterm infants: a longitudinal analysis of a large, varied sample. J Pediatr. 1990;117(2 pt 1):298–307.
-
(1990)
J Pediatr
, vol.117
, Issue.2
, pp. 298-307
-
-
Casey, P.H.1
Kraemer, H.C.2
Bernbaum, J.3
|